{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:07:41Z","timestamp":1781086061403,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1124\/dmd.115.066878","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T01:53:11Z","timestamp":1445910791000},"page":"124-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature"],"prefix":"10.1016","volume":"44","author":[{"given":"Jose Luis","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Tayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.115.066878_bib1","first-page":"233","article-title":"Acute cholestatic hepatitis during simvastatin administration","volume":"82","author":"Ballar\u00e9","year":"1991","journal-title":"Recenti Prog Med"},{"key":"10.1124\/dmd.115.066878_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0891-5520(02)00068-5","article-title":"Clinical pharmacology of antifungal compounds","volume":"17","author":"Groll","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1124\/dmd.115.066878_bib3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1211\/0022357043914","article-title":"Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations","volume":"56","author":"Itagaki","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.115.066878_bib4","first-page":"97","article-title":"[Acute cholestatic hepatitis caused by simvastatin in a 67-year-old patient]","volume":"63","author":"Lata","year":"2006","journal-title":"Przegl Lek"},{"key":"10.1124\/dmd.115.066878_bib5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkm330","article-title":"Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms","volume":"60","author":"Levin","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.115.066878_bib6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.115.066878_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cpem.2005.04.006","article-title":"Drug interactions\u2014a review","volume":"6","author":"Manzi","year":"2005","journal-title":"Clin Pediatr Emerg Med"},{"key":"10.1124\/dmd.115.066878_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066878_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/00498250410001685728","article-title":"Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate","volume":"34","author":"Naritomi","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.115.066878_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.115.066878_bib11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"10.1124\/dmd.115.066878_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.115.066878_bib13","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1177\/0091270010384483","article-title":"Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole","volume":"51","author":"Tsubokura","year":"2010","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624101456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624101456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.115.066878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:22:14Z","timestamp":1739906534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624101456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0090955624101456"],"URL":"https:\/\/doi.org\/10.1124\/dmd.115.066878","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.115.066878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}